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ABSTRACT
Objective: To assess the impact of the Women’s
Health CoOp (WHC) on drug abstinence among
vulnerable women having HIV counselling and testing
(HCT).
Design: Randomised trial conducted with multiple
follow-ups.
Setting: 15 communities in Cape Town, South Africa.
Participants: 720 drug-using women aged 18–33,
randomised to an intervention (360) or one of two
control arms (181 and 179) with 91.9% retained at
follow-up.
Interventions: The WHC brief peer-facilitated
intervention consisted of four modules (two sessions),
2 h addressing knowledge and skills to reduce drug use,
sex risk and violence; and included role-playing and
rehearsal, an equal attention nutrition intervention, and
an HCT-only control.
Primary outcome measures: Biologically confirmed
drug abstinence measured at 12-month follow-up, sober
at last sex act, condom use with main and casual sex
partners, and intimate partner violence.
Results: At the 12-month endpoint, 26.9% (n=83/309)
of the women in the WHC arm were abstinent from
drugs, compared with 16.9% (n=27/160) in the Nutrition
arm and 20% (n=31/155) in the HCT-only control arm. In
the random effects model, this translated to an effect size
on the log odds scale with an OR of 1.54 (95% CI 1.07
to 2.22) comparing the WHC arm with the combined
control arms. Other 12-month comparison measures
between arms were non-significant for sex risk and
victimisation outcomes. At 6-month follow-up, women in
the WHC arm (65.9%, 197/299) were more likely to be
sober at the last sex act (OR1.32 (95% CI 1.02 to 1.84))
than women in the Nutrition arm (54.3%, n=82/152).
Conclusions: This is the first trial among drug-using
women in South Africa showing that a brief intervention
added to HCT results in greater abstinence from drug use
at 12 months and a larger percentage of sexual activity
not under the influence of substances.
Trial registration number: NCT00729391
ClinicalTrials.gov
ARTICLE SUMMARY
Article focus
▪ Drug use is a risk factor for risky sex, gender-
based violence and HIV among vulnerable South
African women.
▪ Few brief woman-focused interventions for drug
use have been evaluated in randomised trials in
Africa.
▪ A randomised controlled trial (RCT) was con-
ducted to assess the impact of the evidence-
based Women’s Health CoOp (WHC) intervention
on drug abstinence among vulnerable women in
addition to having HIV counselling and testing
(HCT) in Cape Town, South Africa.
Key messages
▪ The WHC brief intervention was effective in redu-
cing biologically confirmed drug use 12 months
later when compared with an HCT-only interven-
tion and an HCT plus equal attention nutrition
control intervention.
▪ Drug use often disempowers women from pro-
tecting themselves from adverse sexual conse-
quences and victimisation. An intervention to
reduce drug use in general, and particularly
during sex, is an important first step to reducing
risk.
▪ This brief intervention has been shown to be
effective in an RCT in an HCT setting in a
low-to-middle-income country and among
female drug users with 12-month outcomes.
This intervention was implemented among a
group of vulnerable women and can be easily
translated to other hard-to-reach populations of
drug users.
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Open Access ResearchINTRODUCTION
Illicit drug use is a major public-health problem in
South Africa and it is particularly problematic in the
Western Cape Province.
1–3 Drug use among poor South
African women is of great concern because it places
women at elevated risk for adverse-health outcomes such
as gender-based violence and HIV infection.
4–6 Women
involved with drug use are vulnerable to violence and a
range of risky sex behaviours, including exchanging sex
for drugs or money
5 and inconsistent condom use.
6–8 In
addition, high levels of gender inequity and the disem-
powerment of women in South Africa have a major
impact on women’s ability to protect themselves from
violence to negotiate condom use with sex partners, and
to take control over their drug use.
91 0
Brief interventions in primary healthcare settings to
reduce drug use have been evaluated extensively in high-
income countries, with considerable evidence of their
effectiveness among men.
11 However, owing to insufﬁ-
cient research, the effectiveness of these types of inter-
ventions remains unproven in women who use drugs.
The Women’s Health CoOp (WHC) intervention was
initially developed in the USA as a brief HIV prevention
intervention for African-American women who used
crack cocaine
12 and it is listed as the best-evidence inter-
vention by the Centers for Disease Control and
Prevention.
13 14 Grounded in an empowerment frame-
work and feminist theory, the WHC focuses on increas-
ing women’s knowledge (eg, about drug use and sex-risk
behaviour) and skills (such as sexual negotiation and
condom mastery) to help them reduce their risks for
adverse health outcomes.
14 15 Since its inception, the
WHC has been adapted and tested for sex workers and
other vulnerable women in Pretoria, South Africa,
16
yielding reductions in alcohol use and partner violence
and improvements in condom use at 6-month
follow-up.
14 16 However, as alcohol was the predominant
substance of abuse among participants in the Pretoria
study and because this sample lacked diversity, it is
unclear whether ﬁndings from this study are generalis-
able to other vulnerable South African women. As Cape
Town has an entrenched illicit drug scene characterised
by polysubstance use and an especially high prevalence
of methamphetamine use among vulnerable women,
17
we conducted initial exploratory and pilot studies to
demonstrate feasibility with drug-using women.
18 19
Findings supported our plans to conduct a large rando-
mised controlled trial (RCT) to test whether the WHC
intervention yielded reductions in substance use and
partner violence and improvements in sexual risk when
applied to a more culturally diverse sample with more
illicit drug use.
METHODS
Study design and setting
The study design was a three-armed RCT set in Cape
Town, South Africa, from September 2008 to January
2012. The necessary sample size for achieving acceptable
statistical power was calculated to detect moderate effect
sizes between the WHC arm versus the combined
control arms ranging from 0.26 to 0.50 for the primary
outcome, biologically conﬁrmed drug abstinence. The
sample size required was 900, randomly assigned to the
three groups (450, 225 and 225). Recruitment took
longer than anticipated, because considerable time was
needed to build trust and rapport within the selected
communities so that drug-using women felt comfortable
to participate in the study. Resource constraints also
limited the number of women we could enrol while still
being able to conduct 12-month follow-up interviews
within the project timeframe. Consequently, we enrolled
720 women in the trial, a smaller number of participants
than originally intended. The observed power to detect
differences with the ﬁnal sample size and actual effect
sizes in the study was 0.84 for abstinence from all drugs
at 12 months. There were no interim analyses or stop-
ping guidelines. All statistical tests presented herein are
based on a two-tailed test, assuming an overall signiﬁ-
cance level of α=0.05.
Eligible participants were women of child-bearing age
(18–33 years old), who were living in one of the target
communities, had used at least two drugs (one of which
could be alcohol) at least once a week for the past
3 months, were sexually active with a man in the past
month and had not participated in the pilot study.
19 To
be selected as a target community, areas had to be
deﬁned as a disadvantaged community (ie, areas
reserved for the use of ‘Black African’
* or ‘Coloured’
persons under the Apartheid regime and systematically
deprived of access to services and resources) with high
levels of health and social issues as well as low income.
20
A rigorous sampling plan was developed to ensure a
more balanced recruitment of women across all 15 dis-
advantaged communities. Speciﬁcally, we used commu-
nity population estimates to calculate the desired
sampling targets for each community to ensure a more
representative sample of women from different disadvan-
taged areas in Cape Town.
ARTICLE SUMMARY
Strengths and limitations of this study
▪ A strength is only 8.1% of the sample was lost to follow-up.
▪ There were no significant differences in sexual risk and
gender-based violence between the groups at follow-up.
▪ HCT was carried out in all conditions and may have influenced
the trend of increased condom use in all three study arms.
*The terms “Black African” and “Coloured” refer to demographic
markers that were chosen for their historical signiﬁcance and their
continued relevance in terms of tracking progress in addressing health
disparities in South Africa. “Coloured” refers to a grouping of people
of mixed race ancestry that self-identify as a particular ethnic and
cultural grouping in South Africa.
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Vulnerable women randomised trial outcomesPeer outreach workers recruited participants, distribut-
ing marketing materials in areas frequented by potential
participants, such as beauty parlours and corner shops/
convenience stores. Outreach workers visited these loca-
tions regularly to enhance visibility and build rapport
with community members. They approached potential
participants and requested verbal permission to adminis-
ter a brief screening instrument to assess study eligibility
criteria. If eligible women were interested in the study,
they were scheduled for an appointment for an intake
interview where they were rescreened and enrolled in
the trial after giving informed consent. After consent
was obtained, participants took part in a baseline inter-
view, provided biological specimens for testing and
received HIV counselling and testing (HCT).These
methods have also been described previously.
21 22
Randomisation
After screening, enrolment and baseline assessment, partici-
pants were randomised by computer to the following arms:
WHC (Experimental), Nutrition (Attention-Control) or
HCT-only control. Project staff had no inﬂuence over the
allocation process. Randomisation was determined in group
blocks of eight to ensure that 50% of the participants were
randomised to the WHC arm, 25% to the Nutrition arm
and 25% to the HCT-only arm. The study was sufﬁciently
powered to test half the sample in the WHC arm. The
system was set up by the data manager based in the state of
North Carolina in the USA and tested by key project staff
before the start of the project. Staff members who con-
ducted follow-up interviews were not involved in the inter-
vention or baseline assessments; however, they were not
blinded to study arm. The drug tests for the primary
outcome were also not blinded.
Interventions
The Pretoria WHC intervention
14 16 was ﬁrst adapted
for drug-using women in the Western Cape on the basis
of information obtained during focus groups of
drug-using women
18 and then piloted in a small trial.
19
The WHC intervention is a four-module intervention
conducted over two sessions, with each module lasting
approximately 1 h. This intervention is delivered by a
peer educator who serves as the interventionist to
groups of 4–6 women. The interventionist presents
health information to improve women’s knowledge on
key topics, provides participants with information and
strategies to build skills to reduce their health risks (eg,
condom mastery skills) and gives participants an oppor-
tunity to practice these new skills through role-playing
and rehearsal.
Speciﬁcally, session 1 provides participants with infor-
mation about drug use and risks (module 1) and how
certain sex behaviours can increase HIV risk. This
session also teaches women sexual negotiation skills as
well as corrects male and female condom use (module
2). Session 2 focuses on relationship power as well as
communication and negotiation skills with male
partners (module 3), including myths about rape and
violence against women and strategies for avoiding
potentially violent situations (module 4). Session 2 con-
cludes with developing a personalised risk-reduction
plan for each participant that addresses alcohol and
other drug use, condom use and violence. Women are
also referred for drug abuse treatment and for other
health support as needed. The retention rate for the
WHC intervention was 81.7% (n=294/360).
The Nutrition intervention was an equal attention-
control arm originally sourced from a US curriculum
and adapted with available local food sources and to the
neighbourhood context.
23 This intervention is delivered
by a peer interventionist to groups of 4–6 women and
teaches them about the basic food groups, healthy food
preparation and how to develop a menu while shopping
with little money. The intervention also teaches partici-
pants about exercise. The retention rate for the
Nutrition intervention was 82.9% (150/181).
Both of these adapted interventions were reviewed by
an expert panel and a community advisory board in
Cape Town prior to being implemented in the ﬁeld.
Participants randomised to the third intervention arm
received only HCT comprising standard HIV pretest and
post-test counselling in which participants are prepared
for the test and the possible results of the test. No add-
itional counselling on other topics is provided to partici-
pants during HCT.
Outcome measures
We assessed participants at baseline and at 3, 6, 9 and
12-month postrandomisation. In this article, we present
the 6-month and 12-month follow-up outcomes for the
primary outcome involving drug use. However, we also
present some of the related secondary outcomes, such
as impaired sex from drug use. No biological tests were
conducted at 3-month and 9-month follow-up appoint-
ments as the primary purpose of these appointments
was to maintain retention and rapport. The primary
outcome was a biologically conﬁrmed abstinence from
drug use at 12 months. Participants gave a urine speci-
men that was tested using the four-panel Reditest drug
test (Redwood Toxicology Laboratory) for metham-
phetamine, cocaine, opiates and THC (marijuana).
Urine was also tested for Mandrax (methaqualone) by a
drug testing laboratory in Cape Town using standard gas
chromatography techniques to test for the presence of
methaqualone in urine. A participant testing negative
for all substances was classiﬁed as abstinent for drugs.
Additional outcomes were self-report measures of
sex-risk behaviour and victimisation, assessed using a
standard questionnaire administered by study staff using
Computer-Assisted Personal Interviewing. The survey
asked how often the participants had had sex with their
main partner (and casual partners) in the past month
and how many sex acts were protected. Responses were
coded as having had protected sex with the main
partner if all main partner sex acts were protected, and
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acts with casual partners were protected. Participants
without a casual partner were coded as missing.
Participants were asked items about intimate partner vio-
lence: being slapped, pushed, shoved, kicked, hit with a ﬁst
or something else; dragged; or beaten, choked or burned.
Any participant experiencing intimate partner violence in
the prior 6 months was coded as physically abused.
24 To
measure impaired sex, participants were asked: “This last
time you had sex, did you use drugs (including cannabis)
or alcohol just before or during sex?”’
Ethical approval for the study was granted by the
Institutional Review Boards at RTI International and
Stellenbosch University’s Faculty of Health Sciences. The
study obtained informed consent, which was signed at
each data collection point. Participants were provided
with refreshments and a grocery voucher valued at
ZAR40 (USD5.71) for their time at baseline, ZAR60
(USD8.57) at 6-month follow-up and ZAR80 (USD14.29)
at 12-month follow-up. Health kits with condoms and
toiletries were provided to participants at follow-up
appointments. Referrals for HIV services were provided
as necessary. Any adverse events were reported to the
South African Project Director and the Principal
Investigator, who advised staff on the appropriate action
to take, and to the IRB and the funding agency if neces-
sary. In addition, the appropriate documentation was
completed by project staff members and reported, as
dictated in the ﬁeld operations manual and IRB.
Data analysis
Baseline characteristics to ascertain whether there were
differences between study conditions and overall drop
out by condition were summarised as percentages (or
means) and compared between groups, with t tests for
continuous variables and χ² tests for categorical vari-
ables. SAS V.9.2 was used for all statistical analyses. The
primary study statistician (SN) was not blinded to treat-
ment arm assignment. Therefore, a second study statisti-
cian (AML) ran parallel veriﬁcation analyses and was
blinded to arm assignment.
The primary analytic strategy used to estimate the
impact of treatment on each of the main study outcomes
was a generalised-linear mixed model, with repeated
measures observed at baseline, months 6 and 12. This
resulted in a baseline observation and two follow-up
waves from which to examine the effect of the interven-
tion on primary and secondary outcomes. The planned
comparisons involved differences at 6 and 12 months
between (1) the Control arm versus Nutrition, (2) the
WHC arm versus Nutrition and (3) the WHC arm versus
the Control arm. We also conducted additional tests
between the WHC and the combined control conditions
(Control and Nutrition). The intent-to-treat (ITT) ana-
lyses are presented here with cases that were not
observed because of attrition coded to the negative
outcome. As a stability check for attrition, we also exam-
ined two alternative methods (Last Observation Carried
Forward and All Available Cases).The results were highly
stable across methods so the standard ITT approach is
presented here.
The models included ﬁxed effects for treatment condition
(HCT-only control, Nutrition and WHC arms), time (base-
line, 6 months and 12 months) and a treatment-by-time
interaction. The covariate race was included in the mixed
model because it predicts the probability of missingness
and/or dropout and the Full Information Maximum
Likelihood estimator uses information about race to remove
bias associated with dropout. This approach uses informa-
tion about the dropout mechanism to adjust for the missing
observations of each participant.
The primary statistical tests were the prespeciﬁed con-
trasts between the intervention arms at each time point. As
the recruitment of respondents was nested within 15 com-
munities, the mixed model also included a random effect
for community. For dichotomous outcomes, a logit link
was used for predictors to the binary outcome. The magni-
tude of the estimated differences between arms within
each of the time-speciﬁc contrasts was calculated on the
log-odds scale and exponentiated to create ORs as a stan-
dardised measure of effect size. For the continuously dis-
tributed outcome, the mixed model was used with an
identify link transformation and planned contrasts.
RESULTS
Figure 1 presents the trial proﬁle. Attendance records
showed that 18% of the participants allocated to the WHC
arm and 17% of participants allocated to the Nutrition
arm did not attend their intervention sessions. The
6-month and 12-month follow-up percentages for women
in the WHC, Nutrition and HCT-only arms were all
greater than 85%. The follow-up percentages at 12-month
follow-up were slightly higher than for the 6-month
follow-up, as women could return to the study even if they
had missed their 6-month follow-up appointment. Among
study participants, six deaths occurred, divided equally
across the study arms. All deaths were caused by
HIV-related complications or tuberculosis. Among the par-
ticipants, three were sent to prison (two from the WHC
arm and one from the HCT-only control arm).
Convictions were for house breaking, armed robbery and
possession of an illegal ﬁrearm or drugs. None of the
deaths or arrests was linked to study participation. There
were no serious adverse events related to the study.
Participants’ baseline characteristics are shown in table 1.
Characteristics were similar across the three intervention
arms; except for methamphetamine use, where the
Nutrition arm had higher usage than either the WHC arm
or the HCT-only control arm (p=0.01; table 1).
The descriptive statistics for the study outcomes by
condition are presented in table 2. The estimated treat-
ment effects by study condition and the 95% CIs around
the pairwise comparisons between treatment conditions
are shown in ﬁgure 2. There were differences between
the intervention arms for drug abstinence. At the
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Vulnerable women randomised trial outcomes12-month endpoint, 26.9% of the participants in
the WHC arm were abstinent compared with 16.9% in
the Nutrition arm and 20% in the HCT-only control
arm. In the random effects model (ie, forest plot of
effects shown in ﬁgure 2), this contrast was translated to
an effect size of OR=1.54 (95% CI 1.07 to 2.22; Cohen’s
d=0.238) for the comparison between the WHC arm
and the combined Nutrition arm and HCT-only control
arm. There were changes in the proportion of drug use
between baseline and the 12-month follow-up in all
three arms, but the relative change in the WHC arm was
higher than the combined Nutrition and HCT-only
control arms. When the WHC arm was compared with
the Nutrition arm and HCT-only control arm separately,
no differences were found in drug abstinence for the
comparison with the HCT-only control arm, but the pro-
portion abstinent was higher in the WHC arm than the
Nutrition arm at 12 months (OR 1.73 (95% CI 1.06 to
2.81); Cohen’s d=0.302).
There were differences between the intervention arms
on impairment during last sex. At 6 months, the propor-
tion of women in the WHC arm reporting they were not
impaired during their last sexual encounter was lower
than in the Nutritional arm and HCT-only arm combined.
The difference translates to an OR of 1.32 (95% CI 1.02 to
1.84; Cohen’s d=0.153). Substantively, 65.9% of partici-
pants in the WHC arm reported that they were sober
during their last sex encounter compared with 54.4% of
Figure 1 Flow diagram for the Western Cape Women’s Health CoOp Study.
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signiﬁcant changes over the two time points, with an
increase in the number of participants reporting sobriety
at last sex in the WHC arm (p<0.001). There were no dif-
ferences by intervention arm or time for other outcomes.
DISCUSSION
Drug use is a major problem in the Western Cape
Province of South Africa, with particular concern about
escalating methamphetamine use.
17Although we have
shown different patterns of drug use at baseline,
17 22 the
primary outcome of drug use abstinence at 12 months
after the brief WHC intervention and the reduced preva-
lence of self-reported drug-impaired sex at 6 months are
important ﬁndings. Although it did not reduce other
secondary outcomes involving sexual risk taking or the
proportion of women experiencing partner violence at
12 months more than the control groups, these reduc-
tions in illicit-drug use and drug-impaired sex are
Table 1 Participant demographic characteristics, by treatment condition
Participant characteristics Control Nutrition Women’s
N (% of condition) or mean (SD) N=179 N=181 N=360 Significance
Age, mean (SD) 23.2 (4.3) 23.1 (4.1) 23.1 (4.3) 0.95
Race 0.88
Black African* 78 (43.6%) 81 (44.75%) 165 (45.8%)
Coloured 101 (56.4%) 100 (55.25%) 195 (54.2%)
Currently homeless 0.36
Yes 2 (1.1%) 6 (3.3%) 7 (1.9%)
No 177 (98.9%) 175 (96.7%) 353 (98.1%)
Unemployed 0.15
Yes 155 (86.6%) 168 (92.8%) 325 (90.3%)
No 24 (13.4%) 13 (7.2%) 35 (9.7%)
Education 0.79
11th grade or less 160 (89.4%) 163 (90.1%) 317 (88.1%)
12th grade or more 19 (10.6%) 18 (9.9%) 43 (11.9%)
Have a main sexual partner ≥0.99
Yes 171 (95.5%) 173 (95.6%) 344 (95.6%)
No 8 (4.5%) 8 (4.4%) 16 (4.4%)
Familial history AOD 0.1
Yes 126 (70.4%) 124 (68.5%) 275 (76.4%)
No 53 (29.6%) 57 (31.5%) 85 (23.6%)
Family history of HIV/tuberculosis 0.9
Yes 121 (67.6%) 120 (66.3%) 236 (65.6%)
No 58 (32.4%) 61 (33.7%) 124 (34.4%)
Age of first sex mean (SD) 16.2 (2.8) 16.3 (2.6) 16.1 (2.7) 0.66
Biological HIV status N=171 N=170 N=333 0.96
Negative 137 (80.1%) 135 (79.4%) 263 (79.0%)
Positive 34 (19.9%) 35 (20.6%) 70 (21.0%)
Biological drug use N=179 N=181 N=359
Methamphetamine 0.01
Positive 105 (58.7%) 129 (71.3%) 211 (58.8%)
Negative 74 (41.3%) 52 (28.7%) 148 (41.2%)
Cocaine 0.59
Positive 3 (1.7%) 2 (1.1%) 3 (0.8%)
Negative 176 (98.3%) 179 (98.9%) 356 (99.2%)
Opiates 0.37
Positive 11 (6.2%) 18 (9.9%) 26 (7.2%)
Negative 168 (93.9%) 163 (90.1%) 333 (92.8%)
Mandrax 0.13
Positive 44 (24.6%) 60 (33.1%) 93 (25.9%)
Negative 135 (75.4%) 121 (66.7%) 266 (74.1%)
Marijuana 0.85
Positive 139 (77.7%) 142 (78.5%) 286 (79.7%)
Negative 40 (22.4%) 39 (21.6%) 73 (20.3%)
*The terms ‘Black African’ and ‘Coloured’ refer to demographic markers that were chosen for their historical significance and their continued
relevance in terms of tracking progress in addressing health disparities in South Africa. ‘Coloured’ refers to a grouping of people of mixed race
ancestry that self-identify as a particular ethnic and cultural grouping in South Africa.
AOD, alcohol and other drugs; SD, standard deviation.
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Women are more vulnerable in this setting, and because
drug use exacerbates problems and often further disem-
powers women to be unable to protect themselves sexu-
ally or from victimisation, these ﬁndings provide a basis
on which to build. Therefore, we can report both
strengths and limitations from this brief women’s
intervention.
Strengths
This study is possibly the ﬁrst RCTof a brief intervention
to reduce women’s drug use after 12 months in an HCT
ﬁeld setting in sub-Saharan Africa. The ﬁndings are gen-
erally supported by those of a 6-month evaluation of the
WHC intervention among women in Pretoria who were
not sex workers.
14 Additionally, the ﬁnding that the WHC
intervention in this region was efﬁcacious for reducing
biologically measured drug use in an impoverished and
very violent area is noteworthy. While there was a trend of
declining drug-impaired sex at 6 months, which is poten-
tially important for HIV prevention, this trend was
neither sustained at 12-month postintervention nor did
the interventions impact on violence-related outcomes.
Although the original adaptation of the WHC targeted
more alcohol-abusing sex workers, who notably have
heightened sexual risk and are victimised by numerous
partners,
59the main outcomes showed signiﬁcant reduc-
tions in these risk behaviours. Women within township
communities in Cape Town face illicit drug use as a
major problem
13with earlier studies highlighting the
high prevalence of methamphetamine as well as polydrug
use among vulnerable women from disadvantaged Cape
Town communities.
17 They also face greater exposure to
community violence, particularly traditional male atti-
tudes and gang-related violence.
25 These contextual dif-
ferences between the Pretoria WHC study and the current
study could have contributed to our failure to ﬁnd signiﬁ-
cant reductions in partner violence victimisation and sus-
tained improvements in drug-impaired sex. In addition,
we conducted additional analyses (not presented here) to
understand whether our results were robust to differences
in the composition of Blacks and Coloured respondents in
Table 2 Baseline, 6-month and 12-month key outcome measures, by intervention condition
Descriptive statistics
Control arm Nutrition arm WHC arm
n/total Per cent n/total Per cent n/total Per cent
Abstinence from all drugs
Baseline 7/179 3.9 5/181 2.8 12/359 3.3
Month 6 31/152 20.4 31/152 20.4 74/299 24.7
Month 12 31/155 20.0 27/160 16.9 83/309 26.9
F-test for trend (2df) f=16.4 p<0.001 f=4.1 p<0.001 f=19.7 p<0.001
Protection with main partner
Baseline 40/171 23.4 38/173 22.0 98/344 28.5
Month 6 43/122 35.2 50/133 37.6 93/253 36.8
Month 12 39/120 32.5 54/130 41.5 106/247 42.9
F-test for trend (2df) f=3.87 p=0.022 p=7.81 p<0.001 f=8.75 p<0.001
Protection with casual partner
Baseline 23/32 71.9 26/36 72.2 36/62 58.1
Month 6 11/16 68.8 13/15 86.7 13/22 59.1
Month 12 14/17 82.4 6/10 60.0 23/31 74.2
F-test for trend (2df) f=0.057 p=0.579 f=1.54 p=0.094 f=1.09 p=0.354
No impaired sex, last
Encounter
Baseline 90/179 50.3 90/181 49.7 162/360 45.0
Month 6 86/151 57.0 82/152 54.3 197/299 65.9
Month 12 83/155 53.5 87/160 54.4 191/308 62.0
F-test for trend (2df) f=1.00 p=0.369 f=0.55 p=0.578 f=20.81 p<0.001
No casual partners
Baseline 160/179 89.4 157/181 86.7 313/360 86.9
Month 6 137/151 90.7 144/152 94.7 281/299 94.0
Month 12 144/155 92.9 152/160 95.0 289/308 93.8
F-test for trend (2df) f=0.69 p=0.503 f=5.26 p<0.01 f=6.61 p<0.01
No physical partner violence
Baseline 118/171 69.0 108/173 62.4 230/344 66.9
Month 6 96/122 78.7 104/133 78.2 205/253 81.0
Month 12 90/120 75.0 90/130 75.4 191/247 77.3
F-test for trend (2df) f=2.29 p=0.102 f=5.66 p=0.003 f=9.82 p<0.001
df, degrees of freedom.
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Vulnerable women randomised trial outcomesthe intervention. The ﬁndings indicated no signiﬁcant dif-
ferences by condition, so the intervention appears to
affect both racial groups. Future studies might consider
testing whether the addition of a booster intervention
session after the 6-month follow-up yields sustained reduc-
tions in drug-impaired sex. In addition, brief interventions
such as the WHC generally focus on individual-level contri-
butors to risky behaviours and as such are unlikely to
address structural and contextual determinants of sexual-
risk behaviour or violence. As part of addressing the rela-
tionship context of sexual-risk behaviours, future studies
might incorporate the relationship with male partners into
the intervention. Studies should also consider examining
structural drivers of behaviour change among high-risk
populations, including the role that neighbourhoods and
social networks play in hindering and facilitating behav-
iour change.
26 In addition, future iterations of the WHC
intervention may need to address structural determinants
of partner violence and victimisation;
26 particularly
because only a gender-focused structural intervention has
been effective in reducing partner violence in South
Africa with disadvantaged women.
27 28 Nonetheless, the
gender sessions of the WHC intervention may have been
of considerable value to women.
Limitations
This RCT has several limitations that might affect the
interpretation of the results. First, participants in all
three arms received HCT; consequently, it is possible
that the trend observed across all arms of greater
condom use with a main sex partner could be attribut-
able to HCT. Second, there were more methampheta-
mine users at baseline in the Nutrition arm than either
the WHC arm or the HCT-only control arm, possibly
making change more difﬁcult. However, the proportion
of participants with any biologically conﬁrmed drug use
Figure 2 Plot of treatment main effects, by study outcomes.
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Vulnerable women randomised trial outcomesdid not differ and there were no differences in drug use
between the Nutrition arm and the HCT-only control
arm at 6 or 12 months. Third, the study focused on indi-
vidual behaviour changes and it is possible that these
changes are not sustainable as they do not focus on con-
textual issues as well. Also, the study was not powered to
detect the impact on HIV incidence. Fourth, the
follow-up period was for 12 months; consequently, we do
not know if the intervention effects were sustained
beyond that period. Despite considerable efforts at
cohort retention, 8.1% of participants (58 women)
failed to contribute any data for the outcome analysis.
This compares favourably with other behavioural RCTs.
For example, one study lost 15% to follow-up.
28 As
follow-up rates and intervention attendance rates were
similar in the WHC intervention arm and HCT-only
control arm, this is unlikely to have biased the results.
Finally, the study addressed gender inequality and
gender-based violence. However, working only with
women and not their sexual partner meant that these
issues could not be addressed with men. Future studies
should consider working with women and their sex part-
ners so that these issues can be addressed within the
context of the relationship.
Implications
The WHC brief intervention was effective in reducing
drug use among participants 12 months later when com-
pared with an HCT-only intervention and an HCT plus
equal attention control intervention. In high-income
countries, brief screening interventions for alcohol abuse
have been shown to be effective in primary healthcare set-
tings,
11 but such interventions for other drug use have
been researched very little.
29 To our knowledge, this is the
ﬁrst time a brief intervention has been shown in an RCT
to be of use in an HCT setting in a low-to-middle income
country and among female drug users a year later. Further,
this intervention was implemented among a group of vul-
nerable women and can be easily translated into other set-
tings with hard-to-reach populations of drug-using women.
Consequently, this brief intervention has the potential for
broader dissemination among drug-using populations else-
where. Further, if it is scaled up widely, it may aid efforts
for HCT and to reduce drug abuse among vulnerable
women from high-risk communities.
Future work
Future studies plan to focus on structural drivers of
behaviour change among high-risk populations. This
includes plans to address structural and social networks
in different neighbourhoods of a community. While all
the women in this study can be described as high-risk
and vulnerable, a future aim of studies with this group
will be to explore the characteristics of the sample in
more depth, in order to make conclusions about typolo-
gies of women that had successful outcomes.
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